These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
The vaccine is under FDA review
It is a two dose vaccine to be administered intramuscularly at 28 days apart
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Increased and timely testing will enable early identification of COVID cases and help to curb spread of the infection among the community
Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Subscribe To Our Newsletter & Stay Updated
